Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 9, 2006, Pages 1095-1104

  Nakchbandi, Wes ^a   Müller, Herwart ^a   Singer, Manfred V ^b   Löhr, Matthias ^b   Nakchbandi, Inaam A ^b  

^a Carl von Hess Hospital   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Pancreatic carcinoma; regional chemotherapy; warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC ANTIBIOTIC; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; MITOMYCIN; RIBONUCLEOTIDE REDUCTASE; WARFARIN;

ARTICLE; CARCINOMA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTICOAGULANTS; CARCINOMA; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MITOMYCIN; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; RIBONUCLEOTIDE REDUCTASES; SURVIVAL RATE; TREATMENT OUTCOME; WARFARIN;

EID: 34247560195     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600575720     Document Type: Article

References (45)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de I'Hotel-Dieu. Paris. Bailliere JB 1865; 3: 654–712
2. Sproul E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 566–85
3. Silberberg J, Gordon S, Zucker S. Identification of tissue factor in two human pancreatic cancer cell lines. Cancer Res 1989; 49: 5443–7
4. Kakkar A, Lemoine N, Scully M, Tebbutt S, Williamson R. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101–4
5. Rudroff C, Seibold S, Kaufmann R, et al. Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. Clin Exp Metastasis 2002; 19: 181–9
6. Wojtukiewicz MZ, Rucinska M, Zimnoch L, Jaromin J, Piotrowski Z, Rozanska Kudelska M, et al. Expression of prothrombin fragment 1 + 2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000; 97: 335–42
7. Wojtukiewicz M, Sierko E, Zimnoch L, Kozlowski L, Kisiel W. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 2003; 90: 140–6
8. Andren-Sandberg A, Lecander I, Martinsson G, Astedt B. Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma. Cancer 1992; 69: 2884–7
9. Wojtukiewicz MZ, Rucinska M, Zacharski LR, Kozlowski L, Zimnoch L, Piotrowski Z, et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 2001; 86: 1416–20
10. Kakkar AK, Chinswangwatanakul V, Tebbutt S, Lemoine NR, Williamson RC. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis 1998; 28: 1–6
11. Francis J, Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin Thromb Hemostas 2002; 28: 29–38
12. Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001; 86: 1586–7
13. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981; 245: 831–5
14. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984; 53: 2046–52
15. Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 993–1002
16. Zacharski, LR, Henderson, WG. A rebuttal: vitamin K antagonists and cancer survival. Thromb Haemost 2002;88:173–4; discussion: 175.
17. Maurer LH, Herndon JE, 2nd, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997; 15: 3378–87
18. Cello J. Pancreatic cancer. Sleisenger & Fordtran's gastrointestinal and liver disease. 6th ed, M Feldman, B Scharschmidt, M Sleisenger. W.B. Saunders, Philadelphia 1998; 863–70
19. Goldberg R, Martenson J, Alberts S. Chemotherapy and radiation therapy of pancreatic cancer. Gastrointestinal cancers, A Rustgi. Elsevier Science, Philadelphia 2003; 549–62
20. Collins J. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2: 498–504
21. Ruo, L, DeMatteo, RP, Blumgart, LH. The role of adjuvant therapy after liver resection for colorectal cancer metastases. Clin Colorectal Cancer 2001;1:154–66; discussion: 167–8.
22. Sadrian R, Niederbichler AD, Friedman J, et al. Intra-arterial chemotherapy: the effects on free-tissue transfer. Plast Reconstr Surg 2002; 109: 1254–8
23. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002; 29: 119–25
24. Chen HSG, Gross J. Intra-arterial infusion of anticancer drugs; theoretic aspects of drug delivery and review of responses. Cancer Treat 1980; 64: 31–40
25. Muchmore J, Preslan J, George W. Regional chemotherapy for inoperable pancreatic carcinoma. Cancer 1996; 78: 664–73
26. Ohigashi H, Ishikawa O, Imaoka S, et al. A new method of intra-arterial regional chemotherapy with more selective drug delivery for locally advanced pancreatic cancer. Hepatogastroenterology 1996; 43: 338–45
27. Link K, Gansauge F, Gorich J, Leder G, Rilinger N, Beger H. Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur J Surg Oncol 1997; 23: 409–14
28. Maurer C, Borner M, Lauffer J, Friess H. Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer. Int J Pancreatol 1998; 23: 181–6
29. Cantore M, Pederzoli P, Cornalba G, Fiorentini G, Guadagni S. Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 2000; 11: 569–73
30. Klapdor R, Seutter E, Lang-Polckow E, Reichle H, Hinrichs A. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers. Anticancer Res 1999; 19: 2459–69
31. Homma H, Doi T, Mezawa S, Takada K. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 2000; 89: 303–13
32. Bakkevold KE, Kambestad B. Staging of carcinoma of the pancreas and ampulla of Vater. Tumor (T), lymph node (N), and distant metastasis (M) as prognostic factors. Int J Pancreatol 1995; 17: 249–59
33. Hermanek P. Tumors of the gastrointestinal tract and the pancreas: histopathology, staging and prognosis. Anticancer Res 1999; 19: 2393–6
34. Lüttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Kloppel G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol 2000; 191: 154–61
35. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB, 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270–5
36. Ueda C, Hirohata Y, Kihara Y, et al. Pancreatic cancer complicated by disseminated intravascular coagulation associated with production of tissue factor. J Gastroenterol 2001; 36: 848–50
37. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 2004; 30: 31–44
38. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost 2004; 30: 63–9
39. Mousa SA. Antithrombotics in thrombosis and cancer. Expert Rev Cardiovasc Ther 2003; 1: 283–91
40. Falconi M, Sartori N, Cantore M, et al. Does locoregional chemotherapy improve survival in patients with non-resectable pancreatic carcinoma? Results of an open controlled study. Chir Ital 2001; 53: 23–32
41. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430–8
42. Cosgrove RH, Zacharski LR, Racine E, Andersen JC. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002; 28: 79–87
43. Zacharski LR, Loynes JT. The heparins and cancer. Curr Opin Pulm Med 2002; 8: 379–82
44. Mousa SA. Antithrombotics in thrombosis and cancer. Expert Rev Cardiovasc Ther 2003; 1: 283–91
45. Bobek V, Boubelik M, Fiserova A, L'uptovcova M, Vanucci L, Kacprzak G, et al. Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer 2005; 47: 215–23